Carcinoma in Situ Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer
Condition:   Bladder Cancer Intervention:   Drug: Pembrolizumab (MK-3475) Sponsors:   Memorial Sloan Kettering Cancer Center;   Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 20, 2018 Category: Research Source Type: clinical trials